Vericel Corp (VCEL)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Vericel Corp (VCEL) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011960
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vericel Corp (Vericel) formerly Aastrom Biosciences, Inc. is a medical device company that develops patient-specific expanded cellular therapies to repair and regenerate damaged tissue for the treatment of severe, chronic ischemic cardiovascular diseases. It markets two autologous cell therapy products in the US: Carticel, an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement for the treatment of patients with deep-dermal. The company also develops MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treating advanced heart failure. It has manufacturing facilities in Cambridge, Massachusetts; Ann Harbour, Michigan and Kastrup, Denmark. Vericel is headquartered in Cambridge, the US.

Vericel Corp (VCEL) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vericel Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Vericel Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Vericel Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Vericel Corp, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Vericel Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Vericel Corp, Medical Equipment, Deal Details 10
Innovative Cellular Therapeutics Enters into Licensing Agreement with Vericel 10
Equity Offering 11
Vericel Raises USD19.6 Million in Public Offering of Shares 11
Aastrom Biosciences Raises USD15 Million in Private Placement of Shares 13
Aastrom Biosciences Raises USD40 Million in Public Offering of Shares 14
Aastrom Biosciences Completes Public Offering Of Shares For US$9 Million 16
Vericel Corp – Key Competitors 17
Vericel Corp – Key Employees 18
Vericel Corp – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Nov 07, 2017: Vericel Reports Third-Quarter 2017 Financial Results 20
Aug 09, 2017: Vericel Reports Second-Quarter 2017 Financial Results 22
May 10, 2017: Vericel Reports First-Quarter 2017 Financial Results 24
Mar 10, 2017: Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results 26
Nov 07, 2016: Vericel Reports Third-Quarter 2016 Financial Results 28
Sep 12, 2016: Vericel Enters into Expanded $20 Million Credit Facility and Term Loan with Silicon Valley Bank and MidCap Financial Services 30
Aug 08, 2016: Vericel Reports Second-Quarter 2016 Financial Results 31
May 10, 2016: Vericel Reports First-Quarter 2016 Financial Results 33
Mar 14, 2016: Vericel Reports Fourth-Quarter and Year-End 2015 Financial Results 34
Corporate Communications 36
Apr 10, 2017: Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs 36
Product News 37
03/07/2016: Vericel Announces FDA Acceptance for Filing of BLA for MACI for the Treatment of Symptomatic Cartilage Defects in the Knee 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Vericel Corp, Medical Equipment, Key Facts, 2016 2
Vericel Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Vericel Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Vericel Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Vericel Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Vericel Corp, Deals By Market, 2011 to YTD 2017 8
Vericel Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Innovative Cellular Therapeutics Enters into Licensing Agreement with Vericel 10
Vericel Raises USD19.6 Million in Public Offering of Shares 11
Aastrom Biosciences Raises USD15 Million in Private Placement of Shares 13
Aastrom Biosciences Raises USD40 Million in Public Offering of Shares 14
Aastrom Biosciences Completes Public Offering Of Shares For US$9 Million 16
Vericel Corp, Key Competitors 17
Vericel Corp, Key Employees 18
Vericel Corp, Other Locations 19
Vericel Corp, Subsidiaries 19

★海外企業調査レポート[Vericel Corp (VCEL)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CryoTherapeutics Gmbh:医療機器:M&Aディール及び事業提携情報
    Summary CryoTherapeutics GmbH (CryoTherapeutics) is a medical equipment company that offers systemic drug based approach in combination with a localised device-based therapy. The company offers proprietary cryotherapy system that used for the treatment of coronary artery disease that causes heart at …
  • Phu Hung Securities Company:企業の戦略的SWOT分析
    Phu Hung Securities Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • eNeura Inc-医療機器分野:企業M&A・提携分析
    Summary eNeura Inc (eNeura) formerly eNeura Therapeutics LLC, is a medical device company that offers portable, non-invasive transcranial magnetic stimulation devices for treating migraine. The company offers products such as flagship product and eNeura Spring TMS device. Its SpringTMS device is pla …
  • MOL Hungarian Oil and Gas Plc (MOL):企業の財務・戦略的SWOT分析
    MOL Hungarian Oil and Gas Plc (MOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • QIAGEN N.V.:企業の戦略・SWOT・財務情報
    QIAGEN N.V. - Strategy, SWOT and Corporate Finance Report Summary QIAGEN N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • GrabTaxi Holdings Pte Ltd:企業の戦略的SWOT分析
    GrabTaxi Holdings Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • bebe stores, inc.:企業の戦略・SWOT・財務分析
    bebe stores, inc. - Strategy, SWOT and Corporate Finance Report Summary bebe stores, inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Qualicaps Inc:企業の戦略的SWOT分析
    Qualicaps Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Global Marine Systems Ltd:電力:M&Aディール及び事業提携情報
    Summary Global Marine Systems Limited (Global Marine), a subsidiary of Bridgehouse Marine Limited, is a marine technology and engineering company. It provides submarine cable installation, maintenance and engineering services. Its capabilities include project management, subsea cable installation, s …
  • Hammerson plc:企業のM&A・事業提携・投資動向
    Hammerson plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hammerson plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Laurus Labs Ltd (LAURUSLABS):製薬・医療:M&Aディール及び事業提携情報
    Summary Laurus Labs Ltd (Laurus Labs) is a drug development company that manufactures active pharmaceutical ingredients. The company develops products through its business divisions such as laurus generics, ingredients and synthesis. It offers active pharmaceutical ingredients and intermediates for …
  • Amorepacific Corp:企業の戦略・SWOT・財務情報
    Amorepacific Corp - Strategy, SWOT and Corporate Finance Report Summary Amorepacific Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • EpiVax Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary EpiVax Inc (EpiVax) develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear sequences of amino acids which ac …
  • CryoTherapeutics Gmbh-医療機器分野:企業M&A・提携分析
    Summary CryoTherapeutics GmbH (CryoTherapeutics) is a medical equipment company that offers systemic drug based approach in combination with a localised device-based therapy. The company’s proprietary cryotherapy system is used for the treatment of coronary artery disease that causes heart attacks. …
  • Swissport Tanzania Limited:企業の戦略・SWOT・財務分析
    Swissport Tanzania Limited - Strategy, SWOT and Corporate Finance Report Summary Swissport Tanzania Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Wesfarmers Limited:企業の戦略・SWOT・財務情報
    Wesfarmers Limited - Strategy, SWOT and Corporate Finance Report Summary Wesfarmers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Atara Biotherapeutics Inc (ATRA):企業の財務・戦略的SWOT分析
    Atara Biotherapeutics Inc (ATRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Big 5 Sporting Goods Corp:企業の戦略・SWOT・財務分析
    Big 5 Sporting Goods Corp - Strategy, SWOT and Corporate Finance Report Summary Big 5 Sporting Goods Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Fibra Uno Administracion, S. A. De C. V.:企業の戦略・SWOT・財務分析
    Fibra Uno Administracion, S. A. De C. V. - Strategy, SWOT and Corporate Finance Report Summary Fibra Uno Administracion, S. A. De C. V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Tesla Inc (TSLA):企業の財務・戦略的SWOT分析
    Tesla Inc (TSLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆